Literature DB >> 15148251

Identification of the active metabolite of ticlopidine from rat in vitro metabolites.

Kenji Yoneda1, Ryou Iwamura, Hiroko Kishi, Yoichi Mizukami, Kimiko Mogami, Sei Kobayashi.   

Abstract

1 Ticlopidine is a well-known anti-platelet agent, but is not active by itself in vitro. We identified a metabolite with anti-platelet activity, which was generated after incubation of 2-oxo-ticlopidine with phenobarbital-induced rat liver homogenate in vitro. 2 An active moiety (UR-4501) was isolated by high-performance liquid chromatography after large-scale preparation of metabolites. 3 The chemical structure of UR-4501 was determined by a combination of liquid chromatography mass/mass spectrometry (LC/MS/MS) and nuclear magnetic resonance (NMR) analysis. 4 UR-4501 produced a concentration-dependent inhibition (3-100 microm) of ADP (10 microm)-induced human platelet aggregation, whereas 2-oxo-ticlopidine (3-100 microm) did not elicit inhibitory responses. 5 UR-4501 (10-100 microm) strongly inhibited ADP- and collagen-induced aggregation and slightly inhibited thrombin-induced aggregation. 6 The inhibition of rat washed platelet aggregation by UR-4501 (100 microm) persisted, even after the platelets had been washed twice. 7 These results suggest that UR-4501 is the molecule responsible for the in vivo activities of ticlopidine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148251      PMCID: PMC1574971          DOI: 10.1038/sj.bjp.0705808

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  P2y(12), a new platelet ADP receptor, target of clopidogrel.

Authors:  P Savi; C Labouret; N Delesque; F Guette; J Lupker; J M Herbert
Journal:  Biochem Biophys Res Commun       Date:  2001-05-04       Impact factor: 3.575

2.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

Authors:  Thomas A Clarke; Lucy A Waskell
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

3.  Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.

Authors:  A Sugidachi; F Asai; K Yoneda; R Iwamura; T Ogawa; K Otsuguro; H Koike
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.

Authors:  C J Foster; D M Prosser; J M Agans; Y Zhai; M D Smith; J E Lachowicz; F L Zhang; E Gustafson; F J Monsma; M T Wiekowski; S J Abbondanzo; D N Cook; M L Bayne; S A Lira; M S Chintala
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

5.  Anti-thrombotic action of ticlopidine, a new platelet aggregation inhibitor.

Authors:  M Tomikawa; S Ashida; K Kakihata; Y Abiko
Journal:  Thromb Res       Date:  1978-06       Impact factor: 3.944

6.  Effect of ticlopidine on human platelet responsiveness ex vivo: comparison with aspirin.

Authors:  B Nunn; R Lindsay
Journal:  Thromb Res       Date:  1980-06-15       Impact factor: 3.944

7.  Structure and stereochemistry of the active metabolite of clopidogrel.

Authors:  Jean-Marie Pereillo; Mohamed Maftouh; Alain Andrieu; Marie-Francoise Uzabiaga; Olivier Fedeli; Pierre Savi; Marc Pascal; Jean-Marc Herbert; Jean-Pierre Maffrand; Claudine Picard
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

Review 8.  ADP receptors of platelets and their inhibition.

Authors:  C Gachet
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

9.  Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

Authors:  Zhongren Ding; Soochong Kim; Robert T Dorsam; Jianguo Jin; Satya P Kunapuli
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

Review 10.  Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.

Authors:  C Picard-Fraire
Journal:  Thromb Res Suppl       Date:  1983
View more
  9 in total

1.  The P2Y(12) receptor as a target of antithrombotic drugs.

Authors:  Stephen O'Connor; Gilles Montalescot; Jean-Philippe Collet
Journal:  Purinergic Signal       Date:  2011-06-28       Impact factor: 3.765

Review 2.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

3.  Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.

Authors:  Yingying Mao; Lili Zhang; Jianguo Jin; Barrie Ashby; Satya P Kunapuli
Journal:  Eur J Pharmacol       Date:  2010-06-30       Impact factor: 4.432

4.  Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel .

Authors:  Sean C Gay; Arthur G Roberts; Keiko Maekawa; Jyothi C Talakad; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Biochemistry       Date:  2010-09-15       Impact factor: 3.162

5.  The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.

Authors:  Subhashini Srinivasan; Fozia Mir; Jin-Sheng Huang; Fadi T Khasawneh; Stephen C-T Lam; Guy C Le Breton
Journal:  J Biol Chem       Date:  2009-04-03       Impact factor: 5.157

Review 6.  The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

Authors:  Dominick J Angiolillo
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

7.  Postischemic Long-Term Treatment with Qiangli Tianma Duzhong Capsule Improves Brain Functional Recovery via the Improvement of Hemorrheology and the Inhibition of Platelet Aggregation in a Rat Model of Focal Cerebral Ischemia.

Authors:  Li-Zhi Hong; Wei-Wei Gu; Yong Ni; Min Xu; Lei Yang; Yan-Li Liu; Shi-Ling Yang; Qiang Zhou; Xiu-Mei Gao; Hui-Ling Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-29       Impact factor: 2.629

Review 8.  Microglia and Neuroinflammation: What Place for P2RY12?

Authors:  Albert Gómez Morillas; Valérie C Besson; Dominique Lerouet
Journal:  Int J Mol Sci       Date:  2021-02-06       Impact factor: 5.923

9.  A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs.

Authors:  Milan Remko; Anna Remková; Ria Broer
Journal:  Int J Mol Sci       Date:  2016-03-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.